<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">farmaec</journal-id><journal-title-group><journal-title xml:lang="en">FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology</journal-title><trans-title-group xml:lang="ru"><trans-title>ФАРМАКОЭКОНОМИКА. Современная фармакоэкономика и фармакоэпидемиология</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2070-4909</issn><issn pub-type="epub">2070-4933</issn><publisher><publisher-name>IRBIS LLC</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">farmaec-72</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Methodology</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Методология</subject></subj-group></article-categories><title-group><article-title>THE ANALYSIS OF METHODOLOGIC CHARACTERISTICS OF RESEARCHES ON SOCIAL AND ECONOMIC BURDEN OF DISEASES IN RUSSIA IN THE FRAMES OF DEVELOPMENT OF STANDARD COST OF ILLNESS METHODOLOGY FOR THE HEALTH TECHNOLOGY ASSESSMENT</article-title><trans-title-group xml:lang="ru"><trans-title>Анализ методологических особенностей исследований по изучению социально-экономического бремени заболеваний в РФ в рамках разработки стандартной методики анализа стоимости болезни с целью ее использования в оценке технологий здравоохранения</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Игнатьева</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Ignatyeva</surname><given-names>V. I.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Авксентьева</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Avxentyeva</surname><given-names>M. V.</given-names></name></name-alternatives><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">Российская академия народного хозяйства и государственной службы при Президенте РФ;&#13;
ГБОУ ВПО «Первый МГМУ имени И.М. Сеченова» Минздрава России, Москва<country>Россия</country></aff><aff xml:lang="en">The Russian Presedential Academy of National Economy and Public Administration;&#13;
 The State Education Institution of Higher Professional Training The First Sechenov Moscow State Medical University under Ministry of Health of the Russian Federation<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2014</year></pub-date><pub-date pub-type="epub"><day>23</day><month>03</month><year>2015</year></pub-date><volume>7</volume><issue>3</issue><fpage>3</fpage><lpage>11</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ignatyeva V.I., Avxentyeva M.V., 2015</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="ru">Игнатьева В.И., Авксентьева М.В.</copyright-holder><copyright-holder xml:lang="en">Ignatyeva V.I., Avxentyeva M.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.pharmacoeconomics.ru/jour/article/view/72">https://www.pharmacoeconomics.ru/jour/article/view/72</self-uri><abstract><p>the concept of the relations between public health and national economy has appeared long time ago, but the development of quantitative methods started only in the middle of the XXth century. Until now there are no uninamioulsly accepted methods and approaches for this type of research. The cost of illness method (assessment of social and economic burden of disease) is one of the most widely used. Our objective was to analyze the methodologic characteristics of researches on the cost of illness in Russia for the development of the standard methodology on evaluation of the social and economic burden related to cancers to be used further for the health technology assessment. Materials and methods. Based on the results of studying foreign and national guidelines and publications devoted to the methodological issues of the cost of illness methods, we worked out the criteria list for analysis of the methodological characteristics of this type of research. Further the developed criteria list was used to study the publications on the results of cost of illness studies in Russia. Results. In total we have analyzed 6 publications on cost of illness related to cancers and 10 publications on assessement of burden related to other diseases. The analysis was considerably hampered by the insufficient description of used methods in the majority of publications. Nethertheless we have discovered major discrepancies in the choice of methods and approaches to the assessment of the disease burden, which makes impossible comparison or use of their results for the health technology assessment. Conclusions. The undertaken analysis highlightened the need for development of standardised methods as well as standardised reporting, which would allow use of research results for health technology assessment and decision making on the financing and health care management. </p></abstract><trans-abstract xml:lang="ru"><p>концепция взаимосвязи между здоровьем населения и экономикой страны обсуждается уже длительное время, но разработка методов, оценивающих ее количественно, началась только в середине XX века. Однако единого мнения по поводу используемых подходов и приемов в рамках данного вида исследований не существует до настоящего времени. Один из наиболее часто используемых методов – это оценка социально-экономического бремени (СЭБ), или стоимости заболевания. Целью настоящего исследования был анализ методологических особенностей проведения оценки СЭБ заболеваний в Российской Федерации в рамках разработки единой методики подобного типа исследований для злокачественных новообразований (ЗНО) с целью последующего ее использования при оценке технологий здравоохранения. Материалы и методы. В результате анализа методических рекомендаций и публикаций по методологии проведения оценки СЭБ как в зарубежной, так и в отечественной литературе был сформирован перечень критериев для анализа методических особенностей данного вида исследований. Далее разработанный перечень был использован для анализа найденных публикаций по результатам исследований по изучению СЭБ заболеваний в РФ. Результаты. Всего было проанализировано шесть публикаций по оценке СЭБ ЗНО в РФ и 10 публикаций, в которых оценивалось СЭБ других заболеваний и состояний. Проведение анализа было значительно затруднено очень скудным описанием методики проведения исследований во многих публикациях. Тем не менее, были выявлены значительные расхождения в выборе методических подходов к проведению оценки СЭБ, что делает невозможным сравнение результатов этих исследований и их обобщение в процессе принятия управленческих решений. Заключение. Проведенный анализ подчеркнул необходимость не только разработки единой методик проведения оценки СЭБ, но и стандарта представления результатов данного вида исследований, что обеспечит возможность их использования в процессе оценки технологий здравоохранения и принятия решений по управлению и финансированию здравоохранения.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>социально-экономическое бремя заболева- ний</kwd><kwd>прямые затраты</kwd><kwd>непрямые затраты</kwd><kwd>анализ стоимости болез- ни</kwd><kwd>оценка технологий здравоохранения</kwd></kwd-group><kwd-group xml:lang="en"><kwd>social and economic burden</kwd><kwd>direct costs</kwd><kwd>indirect costs</kwd><kwd>cost of illness</kwd><kwd>health technology assessment</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Базин И.С. и др. Анализ социально-экономического бремени гепатоцеллюлярной карциномы в России. Медицинские технологии. Оценка и выбор. 2010; 2: 22-27.</mixed-citation><mixed-citation xml:lang="en">Bazin I.S. i dr. Meditsinskie tekhnologii. Otsenka i vybor. 2010; 2: 22-27.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Гасымлы Д.Д., Тонконогов А.С. Медико-демографические потери, обусловленные почечно-клеточным раком, в Красноярском крае. Молодой организатор здравоохранения: сборник научных статей студентов и молодых ученых, посвященный памяти проф. В.К. Сологуба / отв. ред. И.П. Артюхов. Красноярск. 2013; 448 с.</mixed-citation><mixed-citation xml:lang="en">Gasymly D.D., Tonkonogov A.S. Medical and demographic losses due to renal cell carcinoma, in the Krasnoyarsk Territory. Young organizer of public health: a collection of scientific articles of students and young scientists dedicated to the memory of Professor. VK Sologub / holes. Ed. IP Artukhov [Mediko-demograficheskie poteri, obuslovlennye poc hechno-kletochnym rakom, v Krasnoyarskom krae. Molodoi organizator zdravookhraneniya: sbornik nauchnykh statei studentov i molodykh uchenykh, posvyashchennyi pamyati prof. V.K. Sologuba / otv. red. I.P. Artyukhov]. Krasnoyarsk. 2013; 448 s.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ефимова Н.В., Никифорова В.А. Оценка величины экономического ущерба, вызванного неблагоприятным состоянием здоровья населения промышленного города. Вестник Санкт-Петербургского Университета. 2008; 11 (4): 196-201.</mixed-citation><mixed-citation xml:lang="en">Efimova N.V., Nikiforova V.A. Vestnik Sankt-Peterburgskogo Universiteta. 2008; 11 (4): 196-201.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ивахненко О.И., Авксентьева М.В., Максимова Л.В. Методы учета непрямых затрат в оценке технологий здравоохранения. Медицинские технологии. Оценка и выбор. 2013; 1: 29-35.</mixed-citation><mixed-citation xml:lang="en">Ivakhnenko O.I., Avksent'eva M.V., Maksimova L.V. Otsenka i vybo r . 2013; 1: 29-35.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Камалова Ф.М. и др. Экономический ущерб, вследствие временной нетрудоспособности, инвалидности и смертности при раке желудка среди лиц трудоспособного возраста. Городское здравоохранение. 2008; 5: 50-51.</mixed-citation><mixed-citation xml:lang="en">Kamalova F.M. i dr. Gorodskoe zdravookhranenie. 2008; 5: 50-51.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Клинико-экономический анализ. Издание 3-е, дополненное, с приложениями. Под ред. П.А. Воробьева. М. 2008б; 778 с.</mixed-citation><mixed-citation xml:lang="en">Clinical and economic analysis. 3rd edition, complemented with applications. Ed. PA Vorobyov. Moscow [Kliniko-ekonomicheskii analiz. Izdanie 3-e, dopolnennoe, s prilozheniyami]. Pod red. P.A. Vorob'eva. M. 2008b; 778 s.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Колбин А.С. и др. Социально-экономическое бремя мерцательной аритмии в Российской Федерации. Клиническая фармакология и терапия. 2010; 19 (4): 17-22.</mixed-citation><mixed-citation xml:lang="en">Kolbin A.S . i dr. Klinicheskaya farmakologiya i terapiya. 2010; 19 (4): 17-22.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Концевая А.В. и др. Социально-экономический ущерб от острого коронарного синдрома в Российской Федерации. Рациональная фармакотерапия в кардиологии. 2011; 7 (2): 158-166.</mixed-citation><mixed-citation xml:lang="en">Kontsevaya A.V. i dr. Ratsional'naya farmakoterapiya v kardiologii. 2011; 7 (2): 158-166.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Крысанов И.С., Ягудина Р.И., Моисеева Т.Н. Оценка стоимости лечения заболевания (на примере диффузной в-крупноклеточной лимфосаркомы). Вестник Росздравнадзора. 2008; 4: 34-39.</mixed-citation><mixed-citation xml:lang="en">Krysanov I.S., Yagudina R.I., Moiseeva T.N. Vestnik Roszdravnadzora. 2008; 4: 34-39.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Куликов А.Ю., Дедюрина Ю.М. Анализ стоимости болезни лечения пациентов, страдающих депрессивными расстройствами, в условиях здравоохранения Российской Федерации. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2011; 4 (1): 24-33.</mixed-citation><mixed-citation xml:lang="en">Kulikov A.Yu., Dedyurina Yu.M. Farmakoekonomika. Sovremennaya farmakoekonomi ka i farmakoepidemiologiya. 2011; 4 (1): 24-33.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Любов Е.Б. и др. Экономическое бремя шизофрении в России. Социальная и клиническая психиатрия. 2012; 22 (3): 36-42.</mixed-citation><mixed-citation xml:lang="en">Lyubov E.B. i dr. Sotsial'naya i klinicheskaya psikhiatriya. 2012; 22 (3): 36- 42.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Малиевский В.А. «Стоимость болезни» при ювенильных артритах. Научно-практическая ревматология. 2006; 2: 96b-96.</mixed-citation><mixed-citation xml:lang="en">Malievskii V.A. Nauchno-prakticheskaya revmatologiya. 2006; 2: 96b-96.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Омельяновский В.В., Авксентьева М.В., Деркач Е.В., Свешникова Н.Д. Анализ стоимости болезни – проблемы и пути решения. Педиатрическая фармакология. 2011; 8 (3): 6-12.</mixed-citation><mixed-citation xml:lang="en">Omel'yanovskii V.V., Avksent'eva M.V., Derka ch E.V., Sveshnikova N.D. Pediatricheskaya farmakologiya. 2011; 8 (3): 6-12.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Омельяновский В.В., Авксентьева М.В., Деркач Е.В., Свешникова Н.Д. Методические проблемы анализа стоимости болезни. Медицинские технологии. Оценка и выбор. 2011; 1: 42-50.</mixed-citation><mixed-citation xml:lang="en">Omel'yanovskii V.V., Avksent'eva M.V., Derkach E.V., Sveshnikova N.D. Otsenka i vybor. 2011; 1: 42-50.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Поддубная И.В., Аксель Е.М., Киприянова Н.С. Злокачественные новообразования и их социально-экономические последствия (Якутск, 1990-2003 гг.). Сибирский онкологический журнал. 2007; 3 (23): 64-68.</mixed-citation><mixed-citation xml:lang="en">Poddubnaya I.V., Aksel' E.M., Kipriyanova N.S. Sibirskii onkologicheskii zhurnal. 2007; 3 (23): 64-68.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Сосновская Е.В., Николаев Н.А. Фармакоэкономические аспекты терапии больных язвенной болезнью желудка на стационарном и амбулаторно-поликлиническом этапах. Саратовский научно-медицинский журнал. 2011; 7 (2): 418-420.</mixed-citation><mixed-citation xml:lang="en">Sosnovskaya E.V., Nikolaev N.A. Saratovskii nauchnomeditsinskii zhurnal. 2011; 7 (2): 418-420.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Социально-экономическое бремя бронхиальной астмы и хронической обструктивной болезни легких в Российской Федерации. Отчет по исследованию. Под ред. В.В. Омельяновского. Региональный благотворительный общественный фонд содействия деятельности в сфере пропаганды здорового образа жизни «Качество жизни». М. 2010; 30 с.</mixed-citation><mixed-citation xml:lang="en">Socio-economic burden of asthma and chronic obstructive pulmonary d isease in the Russian Federation. Research report. Ed. VV Omel'yanovskii. Regional Charitable Foundation to promote activities in the field of health promotion «Quality of Life» [Sotsial'noekonomicheskoe bremya bronkhial'noi astmy i khronicheskoi obstruktivnoi bolezni legkikh v Rossiiskoi Federatsii. Otchet po issl edovaniyu. Pod red. V.V. Omel'yanovskogo. Regional'nyi blagotvoritel'nyi obshchestvennyi fond sodeistviya deyatel'nosti v sfere propagandy zdorovogo obraza zhizni «Ka chestvo zhizni»]. Moscow. 2010; 30 s.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Шаповалова М.А., Бондарев В.А., Корецкая Л.Р. Клинико-экономический анализ «стоимость болезни». Международный журнал прикладных и фундаментальных исследований. 2012; 7: 143-144.</mixed-citation><mixed-citation xml:lang="en">Shapovalova M.A., Bondarev V.A., Koretskaya L.R. Mezhdunarodnyi zhurnal prikladnykh i fundamental'nykh i ssledovanii. 2012; 7: 143-144.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Ющук Н.Д. и др. Социально-экономическое бремя гепатита С: методология оценки и трудности расчета в РФ. Медицинские технологии. Оценка и выбор. 2012; 4: 46-51.</mixed-citation><mixed-citation xml:lang="en">Yushchuk N.D. i dr. Meditsinskie tekhnologii. Otsenka i vybor. 2012; 4: 46-51.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ягудина Р.И., Зинчук И.Ю., Литвиненко М.М. Анализ «стоимости болезни»: виды, методология, особенности проведения в Российской Федерации. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2012; 1: 4-9.</mixed-citation><mixed-citation xml:lang="en">Yagudina R.I., Zinchuk I .Yu., Litvinenko M.M. Farmakoekonomika. Sovremennaya farmakoekonomika i farmakoepidemio logiya. 2012; 1: 4-9.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Abegunde D.O. et al. The burden and costs of chronic diseases in low-income and middle-income countries. The Lancet. 2007; 370 (9603): 1929-1938.</mixed-citation><mixed-citation xml:lang="en">Abegunde D.O. et al. The burden and costs of chronic diseases in low-income and middle-income countries. The Lancet. 2007; 370 (9603): 1929-1938.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Akobundu E., Ju J., Blatt L., Mullins C.D. Cost-of-Illness studies: a review of current methods. Pharmacoeconomics. 2006; 24 (9): 86990. [PubMed: 16942122].</mixed-citation><mixed-citation xml:lang="en">Akobundu E., Ju J., Blatt L., Mullins C.D. Cost-of-Illness studies: a review of current methods. Pharmacoeconomics. 2006; 24 (9): 869- 90. [PubMed: 16942122].</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Akobundu E. et al. Cost-of-Illness Studies. Pharmacoeconomics. 2006; 24 (9): 869-890.</mixed-citation><mixed-citation xml:lang="en">Akobundu E. et al. Cost-of-Illness Studies. Pharmacoeconomics. 2006; 24 (9): 869-890.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Ament A., Evers S. Cost of illness studies in health care: a comparison of two cases. Health Policy. 1993; 26: 29-42.</mixed-citation><mixed-citation xml:lang="en">Ament A., Evers S. Cost of illness studies in health care: a comparison of two cases. Health Policy. 1993; 26: 29-42.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">American Diabetes Association et al. Economic costs of diabetes in the US in 2007. Diabetes care. 2008; 31 (3): 596-615.</mixed-citation><mixed-citation xml:lang="en">American Diabetes Association et al. Economic costs of diabetes in the US in 2007. Diabetes care. 2008; 31 (3): 596-615.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Berger M.L. et al. Health Care Cost, Quality, and Outcomes. ISPOR Book of Terms. International Society for Pharmacoeconomics and Outcomes Research. 2003.</mixed-citation><mixed-citation xml:lang="en">Berger M.L. et al. Health Care Cost, Quality, and Outcomes. ISPOR Book of Terms. International Society for Pharmacoeconomics and Outcomes Research. 2003.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Bloom B.S., Bruno D.J., Maman D.Y., Jayadevappa R. Usefulness of US cost-of-illness studies in healthcare decision-making. Pharmacoeconomics. 2001; 19 (2): 207-13.</mixed-citation><mixed-citation xml:lang="en">Bloom B.S., Bruno D.J., Maman D.Y., Jayadevappa R. Usefulness of US cost-of-illness studies in healthcare decisionmaking. Pharmacoeconomics. 2001; 19 (2): 207-13.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Byford S., Torgerson D.J., Raftery J. Cost of illness studies. Bmj. 2000; 320 (7245): 1335.</mixed-citation><mixed-citation xml:lang="en">Byford S., Torgerson D.J., Raftery J. Cost of illness studies. BMJ. 2000; 320 (7245): 1335.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Centers for disease control and prevention. Division for Heart Disease and Stroke Prevention. Five-Part Webcast on Economic Evaluation. http://www.cdc.gov/dhdsp/programs/nhdsp_program/ economic_evaluation/Module_II/Podcast_II.pdf.</mixed-citation><mixed-citation xml:lang="en">Centers for disease control and prevention. Division for Heart Disease and Stroke Prevention. Five-Part Webcast on Economic Evaluation. http://www.cdc.gov/dhdsp/programs/nhdsp_program/ economic_evaluation/Module_II/Podcast_II.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Chisholm D. et al. Economic impact of disease and injury: counting what matters. BMJ. 2010; 340. http://www.who.int/choice/ publications/Economic_impact_paperBMJ.pdf.</mixed-citation><mixed-citation xml:lang="en">Chisholm D. et al. Economic impact of disease and injury: counting what matters. BMJ. 2010; 340. http://www.who.int/choice/publications/Economic_impact_paperBMJ.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Clabaugh G., Ward M.M. Cost-of-illness studies in the United States: a systematic review of methodologies used for direct cost. Value in Health. 2008; 11 (1): 13-21. [PubMed: 18237356].</mixed-citation><mixed-citation xml:lang="en">Clabaugh G., Ward M.M. Cost-of-illness studies in the United States: a systematic review of methodologies used for direct cost. Value in Health. 2008; 11 (1): 13-21. [PubMed: 18237356].</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Collins D., Lapsley H. The social costs of drug abuse in Australia in 1988 and 1992. Commonwealth Department of Human Services and Health, 1996 Feb [online]. http://www.health.gov.au/internet/main/Publishing.nsf/ Content/health-pubhlth-publicat-document-mono30-cnt.htm.</mixed-citation><mixed-citation xml:lang="en">Collins D., Lapsley H. The social costs of drug abuse in Australia in 1988 and 1992. Commonwealth Department of Human Services and Health. 1996 Feb [online]. http://www.health.gov.au/internet/main/Publishing.nsf/Content/health-pubhlth-publicat-document-mono30-cnt.htm.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Drummond M.F: Methods for the economic evaluation of health care programmes. 3rd edition. Oxford. 2005.</mixed-citation><mixed-citation xml:lang="en">Drummond M.F: Methods for the economic evaluation of health care programmes. 3rd edition. Oxford. 2005.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Frank R.G. et al. Medicaid And Mental Health: Be Careful What You Ask For. Health Aff. January. 2003; 22 (1): 101-113.</mixed-citation><mixed-citation xml:lang="en">Frank R.G. et al. Medicaid And Mental Health: Be Careful What You Ask For. Health Aff. January. 2003; 22 (1): 101-113.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Gold M.R. Siegel J.E. Russell L.B. et al. Cost-Effectiveness in Health and Medicine. New York. 1996.</mixed-citation><mixed-citation xml:lang="en">Gold M.R. Siegel J.E. Russell L.B. et al. Cost-Effectiveness in Health and Medicine. New York. 1996.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Ottawa: Canadian Agency for Drugs and Technologies in Health. 2006. http://www.inahta.org/wpcontent/ themes/inahta/img/AboutHTA_Guidelines_for_the_Economic_ Evaluation_of_Health_Technologies.pdf.</mixed-citation><mixed-citation xml:lang="en">Guidelines for the economic evaluation of health technologies: Canada [3rd Edition]. Ottawa: Canadian Agency for Drugs and Technologies in Health. 2006. http://www.inahta.org/wpcontent/themes/inahta/img/AboutHTA_Guidelines_for_the_Economic_Evaluation_of_Health_Technologies.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Hanly P. et al. Breast and prostate cancer productivity costs: a comparison of the human capital approach and the friction cost approach.Value in Health. 2012; 15 (3): 429-436.</mixed-citation><mixed-citation xml:lang="en">Hanly P. et al. Breast and prostate cancer productivity costs: a comparison of the human capital approach and the friction cost approach.Value in Health. 2012; 15 (3): 429-436.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Hodgson T.A., Meiners M.R. Cost of illness methodology: a guide to current practices and procedures. Milbank Memorial Fund Quarterly. 1982; 60 (3): 429-462.</mixed-citation><mixed-citation xml:lang="en">Hodgson T.A., Meiners M.R. Cost of illness methodology: a guide to current practices and procedures. Milbank Memorial Fund Quarterly. 1982; 60 (3): 429-462.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Hodgson T.A. Costs of illness in cost-effectiveness analysis: a review of the methodology. Pharmacoeconomics. 1994; 6 (6): 536-52.</mixed-citation><mixed-citation xml:lang="en">Hodgson T.A. Costs of illness in cost-effectiveness analysis: a review of the methodology. Pharmacoeconomics. 1994; 6 (6): 536-52.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Introduction and methods: assessing the environmental burden of disease at national and local levels. http://www.who.int/quantifying_ehimpacts/publications/9241546204/en/.</mixed-citation><mixed-citation xml:lang="en">Introduction and methods: assessing the environmental burden of disease at national and local levels. http://www.who.int/quantifying_ ehimpacts/publications/9241546204/en/.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Koopmanshap M. Cost-of-Illness Studies. Useful for Health Policy? Pharmacoeconomics. 1998; 14: 143-148.</mixed-citation><mixed-citation xml:lang="en">Koopmanshap M. Cost-of-Illness Studies. Useful for Health Policy? Pharmacoeconomics. 1998; 14: 143-148.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Larg A., Moss J. R. Cost-of-Illness Studies. Pharmacoeconomics. 2011; 29 (8): 653-671.</mixed-citation><mixed-citation xml:lang="en">Larg A., Moss J. R. Cost-of-Illness Studies. Pharmacoeconomics. 2011; 29 (8): 653-671.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Molinier L., Bauvin E., Combescure C., Castelli C., Rebillard X., Soulié M., Daurès J.P., Grosclaude P. Methodological considerations in cost of prostate cancer studies: a systematic review. Value Health. 2008; 11 (5): 878-885.</mixed-citation><mixed-citation xml:lang="en">Molinier L., Bauvin E., Combescure C., Castelli C., Rebillard X., Soulié M., Daurès J.P., Grosclaude P. Methodological considerations in cost of prostate cancer studies: a systematic review. Value Health. 2008; 11 (5): 878-885.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Murray C.J.L., Lopez A.D. eds. Global comparative assessments in the health sector: disease burden, expenditure and intervention packages. Geneva. 1994.</mixed-citation><mixed-citation xml:lang="en">Murray C.J.L., Lopez A.D. eds. Global comparative assessments in the health sector: disease burden, expenditure and intervention packages. Geneva. 1994.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Rice D.P. Cost of illness studies: what is good about them? Injury Prevention. 2000; 6: 177-179.</mixed-citation><mixed-citation xml:lang="en">Rice D.P. Cost of illness studies: what is good about them? Injury Prevention. 2000; 6: 177-179.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Rice D.P. Cost-of-illness studies: fact or fiction? Lancet. 1994; 344: 1519-20.</mixed-citation><mixed-citation xml:lang="en">Rice D.P. Cost-of-illness studies: fact or fiction? Lancet. 1994; 344: 1519-20.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Rice D.P. Estimating the cost of illness. Health Economic Series No 6. Washington, DC: US Government Priming Office. 1966; 947-6.</mixed-citation><mixed-citation xml:lang="en">Rice D.P. Estimating the cost of illness. Health Economic Series No 6. Washington, DC: US Government Priming Office. 1966; 947-6.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Rosen A.B., Cutler D.M. Challenges in building disease-based national health accounts. Medical care. 2009; 47 (7 Suppl 1): S7.</mixed-citation><mixed-citation xml:lang="en">Rosen A.B., Cutler D.M. Challenges in building disease-based national health accounts. Medical care. 2009; 47 (7 Suppl 1): S7.</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Segel J.E. Cost-of-illness Studies – A Primer. RTI International. http://www.ppge.ufrgs.br/giacomo/arquivos/cd%20congresso%20 gramado/artigos/segel-2006.pdf.</mixed-citation><mixed-citation xml:lang="en">Segel J.E. Cost-of-illness Studies – A Primer. RTI International.http://www.ppge.ufrgs.br/giacomo/arquivos/cd%20congresso%20gramado/artigos/segel-2006.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Shiell A., Gerard K., Donaldson C. Cost of illness studies: an aid to decision-making? Health Policy. 1987; 8: 317-23.</mixed-citation><mixed-citation xml:lang="en">Shiell A., Gerard K., Donaldson C. Cost of illness studies: an aid to decision-making? Health Policy. 1987; 8: 317-23.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Suhrcke M. et al. Economic Consequences of Noncommunicable Diseases and Injuries in the Russian Federation. 2007. http://www. euro.who.int/__data/assets/pdf_file/0005/74741/E89992.pdf.</mixed-citation><mixed-citation xml:lang="en">Suhrcke M. et al. Economic Consequences of Noncommunicable Diseases and Injuries in the Russian Federation. 2007. http://www.euro.who.int/__data/assets/pdf_file/0005/74741/E89992.pdf.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Suhrcke M. et al. The contribution of health to the economy in the European Union. 2005. http://ec.europa.eu/health/archive/ph_ overview/documents/health_economy_en.pdf</mixed-citation><mixed-citation xml:lang="en">Suhrcke M. et al. The contribution of health to the economy in the European Union. 2005. http://ec.europa.eu/health/archive/ph_overview/documents/health_economy_en.pdf</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Suhrcke M. Urban D. Is cardiovascular disease bad for economic growth? Venice: WHO European Office for Investment for Health and Development. 2006.</mixed-citation><mixed-citation xml:lang="en">Suhrcke M. Urban D. Is cardiovascular disease bad for economic growth? Venice: WHO European Office for Investment for Health and Development. 2006.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Tarricone R. Cost-of-illness analysis: What room in health economics? Health Policy. 2006; 77 (1): 51-63.</mixed-citation><mixed-citation xml:lang="en">Tarricone R. Cost-of-illness analysis: What room in health economics? Health Policy. 2006; 77 (1): 51-63.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">The cost of illness handbook. http://www.epa.gov/oppt/coi/.</mixed-citation><mixed-citation xml:lang="en">The cost of illness handbook. http://www.epa.gov/oppt/coi/.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Twigg J.L. The cost of illness, disability, and premature mortality to Russia's economy. Eurasian Geography and Economics. 2005; 46 (7): 495-524.</mixed-citation><mixed-citation xml:lang="en">Twigg J.L. The cost of illness, disability, and premature mortality to Russia's economy. Eurasian Geography and Economics. 2005; 46 (7): 495-524.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">WHO guide to identifying the economic consequences of disease and injury. http://www.who.int/choice/publications/d_ economic_impact_guide.pdf/.</mixed-citation><mixed-citation xml:lang="en">WHO guide to identifying the economic consequences of disease and injury. http://www.who.int/choice/publications/d_economic_impact_guide.pdf/.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">WHO. Preventing chronic diseases: a vital investment: WHO global report. Geneva. 2005.</mixed-citation><mixed-citation xml:lang="en">WHO. Preventing chronic diseases: a vital investment: WHO global report. Geneva. 2005.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Winter Y. et al. Costs of illness in a Russian cohort of patients with Parkinson’s disease. Pharmacoeconomics. 2009; 27 (7): 571-584.</mixed-citation><mixed-citation xml:lang="en">Winter Y. et al. Costs of illness in a Russian cohort of patients with Parkinson’s disease. Pharmacoeconomics. 2009; 27 (7): 571-584.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
